Latest news and press releases about Cue Biopharma, Inc. (CUE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic.
Price
| Price | $34.17 |
| Market Cap | $90M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.34 |
| EV / EBITDA | -0.27 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -100.64% |
| Return on Invested Capital | -86.59% |
| Return on Assets | -63.02% |
| Gross Margin | 100.00% |
| Operating Margin | -96.56% |
| Net Margin | -96.85% |
Related companies: BRNS · COEP · EQ · IOBT · IPSC · MDCX · NRXP
Explore sector: Healthcare · Biotechnology
More sections of CUE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks